Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets

Anke-Peggy Holtorf; Diana Brixner; Brandon Bellows; Abdulkadir Keskinaslan; Joseph Dye; Gary Oderda

Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets

Am Health Drug Benefits. 2012 Nov;5(7):428-38.

Authors

Anke-Peggy Holtorf¹, Diana Brixner², Brandon Bellows³, Abdulkadir Keskinaslan⁴, Joseph Dye⁵, Gary Oderda⁶

Affiliations

¹ Managing Director, Health Outcomes Strategies, Basel, Switzerland.
² Chair, Department of Pharmacotherapy, and Executive Director, Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah, Salt Lake City.
³ Research Associate, Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City.
⁴ Market Pricing Director, Novartis Pharma AG, Basel, Switzerland.
⁵ Clinical Research Consultant, Competitive Health Analytics, a Humana Company, Atlanta, GA.
⁶ Professor and Director, Utah Medicaid Drug Regimen Review Center, and Director, Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City.

PMID: 24991339
PMCID: PMC4031700

Abstract

Background: Health economics and outcomes research (HEOR) is a growing field that provides important information for making healthcare coverage and access decisions. However, there is no standard process for incorporating HEOR into the decision-making process, and the current use of HEOR by healthcare payers remains unknown.

Objectives: To examine how HEOR data are being used by healthcare payers, including managed care organizations today, and how the use of such data is expected to change in the future in relation to access and reimbursement decision-making.

Methods: The Managed Care Survey (MCS) and the Pharmacy & Therapeutics (P&T) Committee Survey (PTS) were distributed to decision makers in the United States. A total of 72 managed care decision makers responded to the MCS and 30 P&T Committee members responded to the PTS from US healthcare organizations that cover from tens of thousands to millions of lives. The goal of these surveys was to understand the current use of HEOR data, perceived barriers and limitations in the use of HEOR, and the expectations for future use, and how these and other factors affect formulary decisions. An international perspective was gained by modifying the MCS based on feedback received at a European conference, and a pilot version was given to individuals in emerging markets across Asia, Latin America, and the Middle East and Africa.

Results: The majority of US respondents to the MCS (74%; N = 53) and to the PTS (77%; N = 23) indicate that HEOR is currently being used in their decision-making process; but the majority of respondents to the MCS (66%; N = 48) also state that quality assessment is limited (quality assessment was not addressed in the PTS). In addition, the majority of respondents to the MCS (82%; N = 59) expect the use of HEOR to increase in the future. Safety and efficacy were reported in the PTS to be the most important factors in the P&T Committee decision-making process, followed by head-to-head comparisons, and cost. The current use of HEOR in Asia, Latin America, and the Middle East and Africa varied widely across respondents.

Conclusion: This study provides an important benchmark of HEOR use in the United States before the implementation of healthcare reform. Between the years 2010 and 2011, HEOR data were used to varying extents across global regions, but their use in the future is likely to increase in relation to access and reimbursement decisions.